Day: June 17, 2024
On 14 June 2024, AS Merko Ehitus Eesti, part of AS Merko Ehitus group, and KMG Infra OÜ signed an addendum to the design and construction contract with Tallinn Urban Environment and Public Works Department for the additional works of the construction of a tram line connecting the Tallinn Old Harbour with Rail Baltic’s Ülemiste passenger terminal.
As a result of additional works and adjustment with the construction price index, the current value of the contract is approximately EUR 43 million, plus value added tax. The scheduled deadline of the works is as before, in February 2025.
About the conclusion of the original contract, AS Merko Ehitus published stock exchange announcement on 9 August 2022.
Under the agreement, a new tram line will be built on a section of approximately 2.5 kilometres, starting at the intersection of Kivisilla/Gonsiori...
Ackermans & van Haare invests in V.Group, a leading provider of marine support services
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Dear shareholder,
Dear Madam, Dear Sir,please find attached our press release.Best regards
Ackermans & van HaarenAttachmentAckermans & van Haare invests in V.Group, a leading provider of marine support services
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
Written by Customer Service on . Posted in Public Companies.
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —
— Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1 exposure —
— Data supported regulatory submission in China accepted in January 2024 —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 17, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that results from ESLIM-01, HUTCHMED’s Phase III trial of sovleplenib (HMPL-523), in adult patients with primary immune thrombocytopenia (“ITP”) in China, were published in The Lancet Haematology. Additional details and subgroup results of the study were also presented on June 14 at the European Hematology Association (“EHA”) 2024 Hybrid Congress as...